GLUCOTRACK REPORTS SUCCESSFUL COMPLETION OF FIRST REPORTED LONG-TERM PRECLINICAL STUDY OF ITS EPIDURAL GLUCOSE MONITORING SENSOR
13 juin 2024 09h19 HE
|
GlucoTrack, Inc.
Completion of the novel epidural continuous glucose monitoring study confirms its potential for providing simplified disease management for patients with painful diabetic neuropathy Rutherford, NJ,...
Article in Nature Scientific Reports Describes Mechanism of Action of SeaStar Medical’s Selective Cytopheretic Device in the Immunomodulation of Excessive Inflammation
07 juin 2024 08h30 HE
|
SeaStar Medical Holding Corporation
DENVER, June 07, 2024 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (Nasdaq: ICU), a commercial-stage medical device company developing proprietary solutions to reduce the consequences of...
SeaStar Medical Announces 25-for-1 Reverse Stock Split
06 juin 2024 08h30 HE
|
SeaStar Medical Holding Corporation
DENVER, June 06, 2024 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (Nasdaq: ICU), a medical device company developing proprietary solutions to reduce the consequences of hyperinflammation...
Autonomix Announces Approval of Protocol Amendment by Ethics Committee Upon Completion of All Lead-In Patients in Ongoing Human Clinical Trial
03 juin 2024 08h15 HE
|
Autonomix Medical, Inc.
Company plans to release topline results from “lead-in” patients (n=5) imminently THE WOODLANDS, TX, June 03, 2024 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ: AMIX) (“Autonomix” or the...
Autonomix Medical, Inc. Reports Full Year 2024 Financial Results and Provides Corporate Update
31 mai 2024 08h05 HE
|
Autonomix Medical, Inc.
Year marked by operational and clinical execution advancing the development of a potential breakthrough technology for the nervous system Continued progress in first study ever to evaluate...
Autonomix Preclinical Study Successfully Demonstrates That Nerve Ablation Can Slow Tumor Metastasis in Pancreatic Cancer
23 mai 2024 09h15 HE
|
Autonomix Medical, Inc.
Results from the preclinical study demonstrated statistically significant reduction of metastases and statistically significant reduction in tumor mass Lori Bisson, Chief Executive Officer...
Manuscript Published on Multiorgan Failure Patients Treated with SeaStar Medical’s Selective Cytopheretic Device Who Achieved Transplant Eligibility
22 mai 2024 08h30 HE
|
SeaStar Medical Holding Corporation
SCD’s ability to improve clinical status of four critically ill pediatric and adult patients across multiple clinical conditions published in Transplantation Direct DENVER, May 22, 2024 (GLOBE...
GLUCOTRACK’S EPIDURAL GLUCOSE MONITORING SENSOR DEMONSTRATES SUCCESSFUL 30-DAY SAFETY & PERFORMANCE IN LONG-TERM PRECLINICAL STUDY
16 mai 2024 08h30 HE
|
GlucoTrack, Inc.
Promising results support the potential of epidural glucose monitoring for simplified disease management for patients with painful diabetic neuropathy Rutherford, NJ, May 16, 2024 (GLOBE NEWSWIRE)...
GLUCOTRACK ANNOUNCES REVERSE STOCK SPLIT
15 mai 2024 16h15 HE
|
GlucoTrack, Inc.
1-for-5 reverse stock split to become effective as of the opening of trading onMay 20, 2024 Rutherford, NJ, May 15, 2024 (GLOBE NEWSWIRE) -- Glucotrack, Inc. (Nasdaq: GCTK) (“Glucotrack” or the...
Autonomix Medical, Inc. (NASDAQ: AMIX) to Participate in the Virtual Investor Closing Bell Series
14 mai 2024 16h15 HE
|
Autonomix Medical, Inc.
Live webcast on Thursday, May 16th at 4:00 PM ET THE WOODLANDS, TX, May 14, 2024 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ: AMIX) (“Autonomix” or the “Company”), a medical device company...